07:00 , Aug 16, 2010 |  BioCentury  |  Finance

Trubion taken out

A lot more money went into autoimmune and cancer company Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) than its current investors are likely to see via Emergent BioSolutions Inc. 's acquisition in a cash and stock deal. But...
07:00 , Jun 26, 2001 |  BC Extra  |  Financial News

Xoma raises $45 million

XOMA, which is in Phase III testing of its Xanelim anti-CD11a monoclonal antibody for psoriasis, raised $45 million through the sale of 3 million shares at $15. The deal was underwritten by U.S. Bancorp Piper...